Catalent's acquisition by Novo Holdings faces regulatory updates. UK sees a preference for Mounjaro over Wegovy. This image ...

The drug candidate is developed based on SNAC technology. Novo Nordisk, a subsidiary of Novo Holdings AS, is a healthcare company with focus on discovering, developing, and manufacturing biological ...

Meanwhile, major financial dealings unfold as McKinsey settles a lawsuit over its opioid crisis advice for Purdue Pharma, and ...

Danish pharma company Novo Nordisk, makers of weight-loss drugs Ozempic and Wegovy, plans to expand production based on a takeover of US health products ma ...

Catalent Inc. (CTLT) and Novo Holdings A/S announced that the companies have fulfilled all regulatory closing conditions for their ...

Novo Holdings will proceed with its $16.5 billion acquisition of Catalent, the companies announced Saturday, after the ...

Novo Nordisk (NVO) announced that as of today, all regulatory closing conditions relating to the review of its pending acquisition of Catalent ...

Danish pharma company Novo Nordisk, makers of weight-loss drugs Ozempic and Wegovy, plans to expand production based on a ...

Novo Holdings in February agreed to buy Catalent to boost output of the popular weight-loss drug Wegovy. According to the ...

Novo Nordisk's (NVO) acquisition of three Catalent (CTLT) production sites to close soon as its parent wins regulatory nod ...

Today represents an important step in our transition to private ownership under Novo Holdings, a leading life sciences investment firm,” said Alessandro Maselli, President and Chief Executive Officer ...

Novo Holdings A S boosted its position in shares of ArriVent BioPharma by 39.3% during the second quarter. Novo Holdings A S now owns 1,500,000 shares of the company’s stock worth $27,825,000 after ...